ScholarLens Back to search
2015•Forum of Clinical OncologyOpen access

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer

Nikolaos Soupos, Κonstantinos Laschos, Evangelos Bournakis, Euthymios Kostouros, Gerasimos Aravantinos

Open full text 0 citations

Abstract

Abstract Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer

Open-access reader

About this research paper

What this paper is about

Abstract Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Abstract Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer

Key concepts: Olaparib, PARP inhibitor, Ovarian cancer, Medicine, Oncology, Germline, BRCA mutation, Cancer research

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer — Research Paper | ScholarLens